FDA Clearance Tracker · P000012
COBAS AMPLICOR (TM) HEPATITIS C VIRUS (HCV) TEST, V2.0
Last checked: Nov 19, 2026Latest source record: Jul 3, 2001 (this decision)Source: openFDAMethods & limitations
Decided
Jul 3, 2001
Approval withdrawn
Time to decision
490 days
Received Feb 29, 2000. Calendar days, including time FDA spent waiting on the applicant.
Pathway
PMA
Device class
Class II
The decision
- FDA number
- P000012
- Device name
- COBAS AMPLICOR (TM) HEPATITIS C VIRUS (HCV) TEST, V2.0
- Applicant
- Roche Molecular Systems, Inc.
- Applicant location
- Pleasanton, CA
- Received
- Feb 29, 2000
- Decided
- Jul 3, 2001
- Decision
- Approval withdrawn
- Expedited review
- Yes, flagged as expedited in FDA's record.
- Supplements
- 51 in FDA's data for this PMA. See them on the FDA record
Device type
- Device class
- Class II
- Regulation
- 21 CFR 866.3170
- Specialty
- Laboratory Medicine & Pathology
FDA's approval statement
As written in FDA's record.
APPROVAL FOR THE COBAS AMPLICOR HEPATITIS C VIRUS (HCV) TEST, V2.0. THE DEVICE IS INDICATED FOR: THE QUALITATIVE DETECTION OF HCV RNA IN HUMAN SERUM OR PLASMA FROM BLOOD COLLECTED IN EDTA (EDTA PLASMA). THE TEST DETECTS BY REVERSE-TRANSCRIBING TARGET HCV RNA INTO CDNA, AMPLIFYING CDNA BY POLYMERASE CHAIN REACTION (PCR), HYBRIDIZING AMPLIFIED CDNA WITH AN OLIGONUCLEOTIDE PROBE THAT BINDS ENZYME, AND CATALYZING CONVERSION OF SUBSTRATE TO A COLORED PRODUCT THAT IS RECOGNIZED BY THE COBAS AMPLICOR ANALYZER. THE COBAS AMPLICOR HCV TEST, V2.0 IS INDICATED FOR PATIENTS WHO HAVE EVIDENCE OF LIVER DISEASE AND ANTIBODY EVIDENCE OF HCV INFECTION, AND WHO ARE SUSPECTED TO BE ACTIVELY INFECTED WITH HCV. DETECTION OF HCV RNA INDICATES THAT THE VIRUS IS REPLICATING AND THEREFORE IS EVIDENCE OF ACTIVE HCV INFECTION.
How new is this?
These are facts about FDA's records. They are not a judgment about the device.
- This is the earliest decision in FDA's data under product code MZP (Assay, hybridization and/or nucleic acid amplification for detection of hepatitis c rna,hepatitis c virus).
- It is not on FDA's public list of Breakthrough Devices with marketing authorization (list dated June 30, 2026). FDA does not publish which devices hold the designation before they are authorized, and the list is updated only a few times a year.
Source documents
Other decisions for Roche Molecular Systems, Inc.
Matched on the applicant name as FDA recorded it. A company that files under several names will have more.
K260045 · Decided Aug 28, 2026 · 233 days after receipt
Device type: C. Difficile Toxin Gene Amplification Assay (OZN) · Laboratory Medicine & Pathology
K260047 · Decided Aug 28, 2026 · 233 days after receipt
Device type: Groups A, C And G Beta-Hemolytic Streptococcus Nucleic Acid Amplification System (PGX) · Laboratory Medicine & Pathology
- cobas® BV/CV510(k)
K260021 · Decided Jul 16, 2026 · 192 days after receipt
Device type: Vaginitis And Bacterial Vaginosis Nucleic Acid Detection System (PQA) · Laboratory Medicine & Pathology
5 more FDA decisions with a free account
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.